Effervescent compositions offer unique advantages such as administration in solution form. They are useful for people with gag reflex or swallowing difficulty and are especially useful for administering medicines to geriatric and pediatric patients. Effervescent compositions from conventional techniques suffer from low carbon dioxide (CO2) content, low porosity, longer disintegration times and have low mechanical strength. STEERLife's advanced patent pending effervescent technologies help create effervescent compositions with increased porosity, rapid disintegration times and high mechanical strength while retaining a greater percentage of CO2 (as compared to the input blend).
EFFERVESCENT TABLETS FOR ORAL SOLUTION
useful for people who have problems swallowing. They are also helpful for improving the bio-availability of various classes of drugs. Converting the dosage forms into effervescent flavoured and sweetened oral solutions can also enhance the acceptability
of the medications.
RAPIDLY DISINTEGRATING TABLETS FOR ORAL SUSPENSION (RDTs)
RDTs are solid unit dosage forms with improved patient compliance. RDTs are especially helpful for children and older people who have problems in swallowing. These tablets disintegrate and disperse rapidly
in a glass of water.
ORALLY DISINTEGRATING TABLETS (ODTs)
ODTs disintegrate with saliva and do not require any external source of liquid for consumption. They are especially useful for patients with dysphagia, or even children who are too young to swallow tablets or capsules.
/ solubility enhancement
STEERLife’s B2C –E and B2C-F technologies help change the physical morphology of API (Active Pharmaceutical Ingredients), for example — from crystalline to amorphous form by solid dispersion/solid solution technology, ultimately enhancing bioavailability and / or solubility.
All STEERLife platform technologies are contained systems and are preferred for production of solid dosage forms of highly potent molecules and active pharmaceutical ingredients such as steroids, hormones and oncology products which require containment for avoiding exposure to personnel and cross contamination.
Drug abuse deterrence
STEERLife’s platform technologies can be used to prepare abuse deterrent formulations designed to reduce misuse of opioids.
Extended release formulations are intended to prolong the drug release over a period of time. They provide for better patient compliance by reducing the frequency of administration. STEERLife’s novel technologies can be used for designing customized extended release systems.
STEERLife’s platform technologies help mask bitter tastes, making it easier for people to take their medicines.